In vitro screening of 50 highly prescribed drugs for thiol adduct formation--comparison of potential for drug-induced toxicity and extent of adduct formation.

Reactive metabolite formation has been associated with drug-induced liver, skin, and hematopoietic toxicity of many drugs that has resulted in serious clinical toxicity, leading to clinical development failure, black box warnings, or, in some cases, withdrawal from the market. In vitro and in vivo screening for reactive metabolite formation has been proposed and widely adopted in the pharmaceutical industry with the aim of minimizing the property and thus the risk of drug-induced toxicity (DIT). One of the most common screening methods is in vitro thiol trapping of reactive metabolites. Although it is well-documented that many hepatotoxins form thiol adducts, there is no literature describing the adduct formation potential of safer drugs that are widely used. The objective of this study was to quantitatively assess the thiol adduct formation potential of 50 drugs (10 associated with DIT and 40 not associated) and document apparent differences in adduct formation between toxic and safer drugs. Dansyl glutathione was used as a trapping agent to aid the quantitation of adducts following in vitro incubation of drugs with human liver microsomes in the presence and absence of NADPH. Metabolic turnover of these drugs was also monitored by LC/UV. Overall, 15 out of the 50 drugs screened formed detectable levels of thiol adducts. There were general trends toward more positive findings in the DIT group vs the non-DIT group. These trends became more marked when the relative amount of thiol adducts was taken into account and improved further when dose and total daily reactive metabolite burdens were considered. In conclusion, there appears to be a general trend between the extent of thiol adduct formation and the potential for DIT, which would support the preclinical measurement and minimization of the property through screening of thiol adduct formation as part of an overall discovery optimization paradigm.

[1]  Ann K. Miller,et al.  Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[2]  A. Kalgutkar,et al.  A semiquantitative method for the determination of reactive metabolite conjugate levels in vitro utilizing liquid chromatography-tandem mass spectrometry and novel quaternary ammonium glutathione analogues. , 2006, Chemical research in toxicology.

[3]  W. Richter,et al.  Biotransformation of diclofenac sodium (Voltaren) in animals and in man. I. Isolation and identification of principal metabolites. , 1979, Xenobiotica; the fate of foreign compounds in biological systems.

[4]  P. Neuvonen,et al.  Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole , 1998, Clinical pharmacology and therapeutics.

[5]  D. Sica,et al.  Clinical Pharmacokinetics of Losartan , 2005, Clinical pharmacokinetics.

[6]  J. Uetrecht.  Idiosyncratic drug reactions: past, present, and future. , 2008, Chemical research in toxicology.

[7]  Dominic P. Williams,et al.  The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man. , 1995, The Journal of pharmacology and experimental therapeutics.

[8]  T. Baillie,et al.  Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. , 2001, Chemical research in toxicology.

[9]  C. D. Thompson,et al.  Mechanisms of idiosyncratic drug reactions: the case of felbamate. , 2002, Chemico-biological interactions.

[10]  T. Baillie,et al.  Future of toxicology-metabolic activation and drug design: challenges and opportunities in chemical toxicology. , 2006, Chemical research in toxicology.

[11]  Zhengyin Yan,et al.  DETECTION OF A NOVEL REACTIVE METABOLITE OF DICLOFENAC: EVIDENCE FOR CYP2C9-MEDIATED BIOACTIVATION VIA ARENE OXIDES , 2005, Drug Metabolism and Disposition.

[12]  T. Baillie,et al.  Minimizing metabolic activation during pharmaceutical lead optimization: progress, knowledge gaps and future directions. , 2008, Current opinion in drug discovery & development.

[13]  C. Siegers,et al.  Biliary and renal excretion of paracetamol in man. , 1984, Pharmacology.

[14]  G. Sachs,et al.  The pharmacology of the gastric acid pump: the H+,K+ ATPase. , 1995, Annual review of pharmacology and toxicology.

[15]  Munir Pirmohamed,et al.  The role of metabolic activation in drug-induced hepatotoxicity. , 2005, Annual review of pharmacology and toxicology.

[16]  T. Gillespie,et al.  Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[17]  T. Hartung,et al.  Thiazolidinedione bioactivation: a comparison of the bioactivation potentials of troglitazone, rosiglitazone, and pioglitazone using stable isotope-labeled analogues and liquid chromatography tandem mass spectrometry. , 2006, Chemical research in toxicology.

[18]  J. Leeder,et al.  PATHWAYS OF CARBAMAZEPINE BIOACTIVATION IN VITRO: II. THE ROLE OF HUMAN CYTOCHROME P450 ENZYMES IN THE FORMATION OF 2-HYDROXYIMINOSTILBENE , 2005, Drug Metabolism and Disposition.

[19]  E. Gillam,et al.  Bioactivation of phenytoin by human cytochrome P450: characterization of the mechanism and targets of covalent adduct formation. , 1997, Chemical research in toxicology.

[20]  D. Thompson,et al.  Role of Metabolism in Drug-Induced Idiosyncratic Hepatotoxicity , 2005, Critical reviews in toxicology.

[21]  J. Clements,et al.  Clinical Pharmacokinetics of Paracetamol , 1982, Clinical pharmacokinetics.

[22]  A. Bridges,et al.  Metabolic activation of troglitazone: identification of a reactive metabolite and mechanisms involved. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[23]  Yue Chen,et al.  IDENTIFICATION OF A NOVEL GLUTATHIONE ADDUCT OF DICLOFENAC, 4′-HYDROXY-2′-GLUTATHION-DESCHLORO-DICLOFENAC, UPON INCUBATION WITH HUMAN LIVER MICROSOMES , 2005, Drug Metabolism and Disposition.

[24]  C. Kaye,et al.  A review of the metabolism and pharmacokinetics of paroxetine in man , 1989, Acta psychiatrica Scandinavica. Supplementum.

[25]  Elizabeth M Joshi,et al.  In vitro metabolism of 2-acetylbenzothiophene: relevance to zileuton hepatotoxicity. , 2004, Chemical research in toxicology.

[26]  A. Kalgutkar,et al.  NADPH-dependent covalent binding of [3H]paroxetine to human liver microsomes and S-9 fractions: identification of an electrophilic quinone metabolite of paroxetine. , 2007, Chemical research in toxicology.

[27]  S. Iverson,et al.  Identification of a reactive metabolite of terbinafine: insights into terbinafine-induced hepatotoxicity. , 2001, Chemical research in toxicology.

[28]  H. Stierlin,et al.  Biotransformation of diclofenac sodium (Voltaren) in animals and in man. II. Quantitative determination of the unchanged drug and principal phenolic metabolites, in urine and bile. , 1979, Xenobiotica; the fate of foreign compounds in biological systems.

[29]  T. Baillie,et al.  Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. , 2004, Chemical research in toxicology.

[30]  F Peter Guengerich,et al.  Applying mechanisms of chemical toxicity to predict drug safety. , 2007, Chemical research in toxicology.

[31]  C. Prakash,et al.  High performance liquid chromatography/atmospheric pressure ionization/tandem mass spectrometry (HPLC/API/MS/MS) in drug metabolism and toxicology. , 2006, Current drug metabolism.

[32]  G. Mannens,et al.  Absorption, metabolism, and excretion of risperidone in humans. , 1993, Drug metabolism and disposition: the biological fate of chemicals.

[33]  W. Humphreys,et al.  Screening and identification of GSH-trapped reactive metabolites using hybrid triple quadruple linear ion trap mass spectrometry. , 2007, Chemical research in toxicology.

[34]  M. Pirmohamed,et al.  Enzyme-induction dependent bioactivation of troglitazone and troglitazone quinone in vivo. , 2001, Chemical research in toxicology.

[35]  E. Randinitis,et al.  Clinical Pharmacokinetics of Troglitazone , 1999, Clinical pharmacokinetics.

[36]  R Scott Obach,et al.  Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose. , 2008, Chemical research in toxicology.

[37]  R. Peter,et al.  Metabolism of (R)-(+)-pulegone and (R)-(+)-menthofuran by human liver cytochrome P-450s: evidence for formation of a furan epoxide. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[38]  J R Gillette,et al.  The role of biotransformation in chemical-induced liver injury. , 1976, Environmental health perspectives.

[39]  J. Yergey,et al.  Verlukast (MK-0679) conjugation with glutathione by rat liver and kidney cytosols and excretion in the bile. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[40]  R. Subramanian,et al.  Detecting and characterizing reactive metabolites by liquid chromatography/tandem mass spectrometry. , 2006, Journal of mass spectrometry : JMS.

[41]  J. Harten.  Clinical Pharmacokinetics of Selective Serotonin Reuptake Inhibitors , 1993 .

[42]  K E Karlsson,et al.  A metabolic route of omeprazole involving conjugation with glutathione identified in the rat. , 1992, Drug metabolism and disposition: the biological fate of chemicals.

[43]  M. Monshouwer,et al.  Analytical Tools and Approaches for Metabolite Identification in Early Drug Discovery , 2007, Pharmaceutical Research.

[44]  Wei Tang.  The metabolism of diclofenac--enzymology and toxicology perspectives. , 2003, Current drug metabolism.

[45]  M. Pirmohamed,et al.  An investigation of the formation of cytotoxic, protein-reactive and stable metabolites from carbamazepine in vitro. , 1992, Biochemical pharmacology.

[46]  Jinping Gan,et al.  Dansyl glutathione as a trapping agent for the quantitative estimation and identification of reactive metabolites. , 2005, Chemical research in toxicology.

[47]  W. P. Gordon,et al.  Investigations of mechanisms of reactive metabolite formation from (R)-(+)-pulegone. , 1992, Xenobiotica; the fate of foreign compounds in biological systems.

[48]  W. Trager,et al.  Oxidation of acetaminophen to its toxic quinone imine and nontoxic catechol metabolites by baculovirus-expressed and purified human cytochromes P450 2E1 and 2A6. , 1998, Chemical research in toxicology.

[49]  J. Uetrecht,et al.  A comparison of the oxidation of clozapine and olanzapine to reactive metabolites and the toxicity of these metabolites to human leukocytes. , 1998, Molecular pharmacology.

[50]  N. Davies,et al.  Clinical Pharmacokinetics of Diclofenac , 1997, Clinical pharmacokinetics.

[51]  Wei Yang Lu,et al.  Pathways of Carbamazepine Bioactivation in Vitro. III. The Role of Human Cytochrome P450 Enzymes in the Formation of 2,3-Dihydroxycarbamazepine , 2008, Drug Metabolism and Disposition.

[52]  T. Baillie,et al.  Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation. , 2002, Chemical research in toxicology.